reason report
strong quarter expens burden drag outlook outperform
pt
result beat consensu expect revenu
earn re-affirmed initi financi guidanc
provid januari top-lin beat driven strong eylea
perform across geographi dupix sale beat
consensu estim encourag see
increas commerci invest regeneron recent incur
correl well revenu growth dupix praluent kevzara
although becom increasingli skeptic likelihood
product meet long-term revenu forecast
anticip sg expens continu increas next
quarter regeneron reinforc market effort praluent
outcom data dupix launch asthma
pediatr eczema indic first co-market cancer
drug cemiplimab launch first glanc appear
regeneron stock perform throughout close link
on-going launch trajectori dupix praluent cemiplimab
sever catalyst panorama data data report
eylea competitor potenti result one-off adjust stock
price second half expect regeneron
sever meaning clinic catalyst remain follow
odsyssey outcom data panorama result eylea
dupix phase trial nasal polyp atop dermat pediatr
cemiplimab basal cell carcinoma provid upsid opportun
estim
follow result made signific adjust
revenu earn forecast decreas revenu
estim futur year due moder launch
expect dupix flat start due reimburs delay
praluent ditto addit increas estim
oper expens come year expect regeneron
invest commerci infrastructur sever drug launch
year addit spend advanc number
earli clinic program area immuno-oncolog inflammatori
diseas muscl biolog updat revenu ep forecast
remain substanti recent consensu result
variou chang chang peer multipl price target
decreas reiter outperform
regeneron stock regn stock like suffer along
peer next month least earli march present
odyssey outcom trial result march catalyst
valu upsid like occur half year
averag price-to-earnings p/ dcf
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu mm dilut ep non-gaap
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
price target regeneron stock rate outperform regeneron
veteran biopharmaceut compani come initi base portfolio fast-
follow second entrant rapidli grow biopharmaceut market first product eylea
continu surpris investor taken grow market intraocular
vegf vascular endotheli growth factor antibodi treatment eylea contribut nearli
global sale trump categori pioneer roch lucenti well
cheaper altern bevacizumab remain posit eylea expect continu
grow lose market share emerg competitor
abicipar like view gain approv excit aspect compani
next wave innov antibodi notabl dupix await approv
first like multipl allerg diseas indic expect dupix
dupilumab gener revenu signific upsid indic
longer term regeneron wholli own antibodi could contribut meaning
revenu earn growth period current compani invest
mode result earn cash flow convers revenu lag peer
industri anticip cash flow true earn improv period
profit antibodi collabor sanofi begin accumul
regeneron report total revenu consensu
forecast led above-consensu sale eylea geographi dupix sale
us eylea sale unit state beat consensu
estim ex-u eylea sale qoq consensu
estim manag team state us eylea sale benefit
slight increas inventori period dupix sale significantli
consensu estim fourth quarter sale almost entir
us number prescrib last quarter first
prescript renew rate regeneron see substanti upsid opportun continu
growth dupix given observ prescrib still offer drug
sever atop dermat patient mani dermatologist still navig often
convolut process obtain payer reimburs even dupix well establish
formulari disclosur consist market research indic
insur requir extens workup paperwork reimburs dupix
even elig patient regeneron state see new brand prescript
everi week end
praluent sale consensu forecast
sanofi op collabor revenu vs consensu vs lp
decreas qoq due full util annual cap reimburs relat
antibodi discoveri agreement first month year revenu recur
sanofi overal reimburs contribut bayer collabor
revenu higher consensu expect driven
royalti ex-u sale eylea
gross oper margin beat consensu estim gross margin
beat consensu oper margin beat total non-gaap
expens qoq consensu line
estim forma expens consensu
estim forma sg consensu
expect manag note higher sg spend quarter relat
on-going invest dupix kevzara launch well season
commerci expens eylea launch prepar cemiplimab regeneron also fund
certain discretionari expens normal would occur earli
order secur tax benefit tax expens
lower consensu estim regeneron previous guid lower tax rate quarter
due benefit vest exercis employe stock option around end year
non-gaap dilut ep substanti higher consensu
expect regeneron report cash market secur end
slightli decreas dilut share count million million
januari regeneron offer initi guidanc non-gaap unreimburs non-gaap
sg effect tax rate capit expenditur sanofi reimburs commerci
relat expens call regeneron re-affirmed previou guidanc
consist prior statement regeneron provid sale guidanc eylea
key product non-gaap unreimburs sg compani expect
bracket current forecast regeneron
expect non-gaap sg expens vs recent consensu
regeneron also guid capit expenditur sanofi commerci relat
reimburs year
continu launch trajectori dupix cemiplimab praluent key variabl
regeneron near mid-term revenu growth matur competit dynam
anti-vegf space disclosur regeneron earli stage muscl bispecif
antibodi program like determin compani long-term prospect dupix
exceed consensu estim everi quarter far launch atop dermat
believ consensu estim soon close approxim street forecast
due perform regeneron still report signific increas prescrib base
versu suggest moder ad popul still
minim penetr offer substanti upsid addit expect approv
sbla dupix uncontrol asthma second half creat
entir new treatment categori drug inflammatori asthma phenotyp
non-inflam low eosinophil popul longer term combin benefit offer
dupi also secur domin posit patient allerg triad
combin symptom asthma allerg rhiniti and/or atop dermat ad believ
continu strength dupix launch next year result double-digit increas
consensu sale estim beyond close approach updat forecast
increas consensu estim come continu strength launch ad
yet begun report meaning sale outsid us file addit
popul pediatr fda approv asthma
regeneron alreadi begun make invest commerci antibodi
cemiplimab expect receiv fda approv cutan squamou cell carcinoma
cscc around mid-year regeneron use initi rel obscur indic start
point broader immuno-oncolog franchis would incorpor bispecif program
earli stage asset combin antibodi despit sort
combin sever year away approv compani suggest could
substanti upsid base initi cscc indic alon regeneron believ cscc peak
could offer similar commerci opportun melanoma evolv billion dollar
plu indic checkpoint inhibitor despit proclam neither consensu give
much valu product launch stori second half event base
acceler approv rel rapid launch adopt reimburs current consensu
sale cemiplimab forecast year
praluent disappoint launch could revit report odyssey
outcom data one month becom increasingli cautiou
trajectori product regardless trial outcom regeneron still blind data
howev continu market invest american colleg cardiolog select
present kick annual confer suggest posit bia result
consid consensu sale forecast cut half past month
combin increas market effort better-than-anticip cardiovascular
outcom data could boost near- long term revenu forecast recov share
valu lost sinc peak
top-lin result phase panorama trial eylea diabet retinopathi becom
avail first half year follow sbla submiss could expand
indic eylea larger popul diabet eye diseas regeneron also
announc present phase odyssey outcom result american
colleg cardiolog meet march earn call yesterday sanofi express
confid efficaci safeti praluent look forward see sale inflect
point base potenti guidelin updat result posit opportun label
expans could come recent launch dupix pend success two phase trial
adolesc patient year old atop dermat nasal polyp anoth piec
pivot data would cemiplimab basal cell carcinoma quickli expand
scope regeneron i/o lead product anoth indic far mostli overlook
follow posit data phase liberti asthma ventur trial report
fourth quarter last year regeneron promptli submit sbla asthma patient age
year older approv could grant fourth quarter year think
addit indic boost growth dupix face somewhat unfavor payer
reaction exist indic secondli regeneron plan finish roll submiss
bla cemiplimab cutan squamou cell carcinoma cscc first quarter potenti
seek acceler approv base prioriti review exist breakthrough statu
soon manag hope opportun indic
possibl compar melanoma platform establish futur
combin vaccin and/or bispecif antibodi develop
regeneron partner sanofi fulli commit dupix recent initi phase
trial eosinophil esophag eoe phase ii studi peanut allergi grass allergi
clinic program copd co-morbid allerg condit compani il-
antibodi investig asthma copd atop dermat support
preclin evid may work synergist dupix
convers compani manag appear confid strong efficaci
clean safeti profil dupix believ unparallel breadth pipelin candid
give compani strong posit allerg inflammatori diseas
regardless evolv competit environ initi trial cscc
cemiplimab final test major indic lung cancer regeneron plan start
phase trial first-lin second-lin non-smal cell lung cancer nsclc
hope captur share lucr market given result gener far
competitor think success nsclc almost certainli requir form
combin therapi well care chosen biomark although remain unclear
therapi regeneron plan combin cemiplimab segment patient
popul target
manag discuss us rational target activin
ultra rare diseas fibrodysplasia ossifican progressiva fop may differenti
product compet drug target myostatin pathway compani also evalu
kevzara two phase trial giant cell arter polymyalgia rheumatica
base quarterli result compani commentari made signific
chang revenu earn forecast decreas consensu
revenu estim futur year mostli base cautiou view
medium-term trajectori dupix praluent decreas
remain consensu dupix year continu forecast peak
sale excess revis total revenu forecast recent consensu
consensu futur year also increas oper
expens estim futur year due busi launch schedul sever drug
period assumpt expens increas rapid rate
earlier stage program compani bispecif antibodi move larger clinic
trial revis sg forecast higher result
chang consequ estim oper margin grow slower rate
versu previous also forecast effect tax rate
futur year versu previous pro forma dilut ep estim
decreas beyond although remain recent consensu
estim forecast pro forma dilut ep grow
result chang well chang peer compani multipl updat
price target previous continu see consider upsid
regeneron stock reiter outperform rate
price target regeneron base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar high growth larg molecul biopharmaceut compani price
sale multipl larg cap high growth compani discount cash flow dcf use
averag larg cap larg molecul therapeut compani nvo
earn multipl ep appli current ep estim
give valu use high growth revenu multipl similar compani
nvo consensu sale appli revenu
estim give valu lastli dcf valuat given wacc
termin cash flow growth rate give present valu averag
three method current price target
risk view outlook valuat regeneron includ major chang price
reimburs coverag label competit posit eylea compani main
product today risk includ commerci develop disappoint compani
next partner program launch dupix kevzara well continu weak
demand compani cholesterol treatment praluent subsequ releas
cardiovascular outcom data regeneron fail match cardiovascular outcom
demonstr rival mp product would advers affect
revenu outlook valuat lastli compani convert rel littl
revenu cash flow today histori return cash investor ultim
may undermin valu stock investor willing continu
sale
collabor
share count period dilut mm
guidanc
tax non-gaap pre-tax incom
sanofi reimburs regeneron
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time event
phase panorama result patient without
dme sbla submiss
phase result adolesc patient year
age
fda approv dose interv
fda approv use apheresi
fda approv adult/adolesc patient
sbla submiss adolesc patient
year age
initi phase ii studi adjunct
homozyg
asthma copd
leerink partner research compani report present clinicaltri gov
initi phase studi
copd co-morbid
eu japan regulatori submiss
sbla submiss pre-fil syring
late stage pipelin program includ
late stage pipelin program exclud
praluent outcom
eylea dr w/o dme
nsclc basal cell
million
leerink partner research compani file
million
good sold
research develop
sell gener administr
collabor manufactur
 total revenu
sg total revenu
leerink partner research compani file
analysi stock price leerink partner target regeneron
method high growth larg cap growth biotech ep multipl
current larg cap larg molecul therapeut compani multipl
leerink partner forma ep estim
impli price ep
equiti
number period
method larg cap growth biopharma forward multipl enu
discount
larg cap high growth biopharma price/sal multipl nvo
leerink partner revenu forecast
impli ev revenu
share count
ev per share
expect net per share
net expect valu per share
equiti
number period
impli share price
present valu po adjust flow
pv termin valu
net
share count
averag method
leerink partner research compani file factset
